The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
 
Edward M. Uchio
Research Funding - Ambry Genetics; Bayer; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Exact Sciences; GenomeDx; Genomic Health; Janssen Oncology; Merck; Merit Medical Systems; Myovant Sciences; Myovant Sciences; Myriad Genetics; Pfizer; Seagen; Veracyte
(OPTIONAL) Uncompensated Relationships - Bayer; Genomic Health; Janssen Oncology; Merck; Myriad Genetics; Pfizer
 
Donald L. Lamm
Research Funding - US Biotest
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Eisai; EnGeneIC; FerGene; Imagin Medical; Janssen; Medac; Merck; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FerGene; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Photocure; Seagen; SWOG; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Mark Tyson
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Paul Anderson
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Paola Grandi
Employment - CG Oncology
Stock and Other Ownership Interests - Oncorus; Oncorus (I)
Consulting or Advisory Role - Oncorus (I)
Patents, Royalties, Other Intellectual Property - Univ. of Pittsburgh; Univ. of Pittsburgh (I)
 
James M. Burke
Employment - CG Oncology
Leadership - CG Oncology
Stock and Other Ownership Interests - CG Oncology; OncoMyx Therapeutics
Consulting or Advisory Role - OncoMyx Therapeutics